Levi joined Samsara BioCapital as a Senior Analyst in 2021. Prior to Samsara, Levi was a Research Investigator at Halda Therapeutics where he co-led the discovery of novel heterobifunctional small molecules for undisclosed oncology targets. Before joining Halda, Levi was a Venture Fellow for Canaan Partners. As a Ph.D. candidate at Yale, Levi’s research focused on the discovery of small molecules for the treatment of Alzheimer’s disease. Projects and targets he worked on included repurposing near-drugs as well as the discovery of novel modulators of cellular prion protein,mGluR5, and Fyn kinase. Prior to Yale, Levi received his Pharm.D. from Butler University with an emphasis in molecular pharmacology.